Evotec Extends Anti-Infectives Footprint With Helmholtz Collaboration

Building on a leading position in anti-infectives research, Evotec aims to develop a new class of antibacterials based on cystobactamids, which are found in slime bacteria and have potent activity against serious bacterial pathogens.  

OrangeBacteria
Slime bacteria are a relatively new resource for new antibiotics • Source: Shutterstock

Nature has long proven to be a great source of novel antibiotics, and the European drug discovery and development company, Evotec AG, is linking up with a leading research institute in Germany, the Helmholtz Center for Infection Research (HZI), to develop cystobactamids, potentially a new class of antibiotics which are found in myxobacteria, or slime bacteria.

This is the latest collaboration by Evotec to feature a major center of academic excellence in infection research: the Hamburg,...

More from Anti-infective

More from Therapy Areas